Quality Engineer - Advanced Wound Care

James River Home Health selects Medline vendor. Medline announced it signed a new Prime Vendor agreement with James River Home Health & Hospice, a home health and hospice provider serving patients and families across its care network, a James River Home Health Medline Prime Vendor arrangement aimed at supporting the provider's growth. What the James River Home Health Medline Prime Vendor agreement includes. Through the agreement, James River gains access to Medline's medical-surgical product portfolio and distribution capabilities, intended to streamline ordering and timely, reliable delivery of supplies. The Prime Vendor model typically consolidates a provider's purchasing with one distributor, which can simplify logistics and standardize the products clinicians use. Clinical tools added to the arrangement. James River will also implement Medline's Skin Health Program and use the NE1 Wound Tool, which helps clinical staff assess and document wounds. Pairing supply purchasing with clinical programs suggests the agreement is meant to support care consistency as well as procurement. James River's rationale for the James River Home Health Medline Prime Vendor deal. David Gilligan, CFO of James River Home Health & Hospice, described the organization as a growing provider focused on expanding access to high-quality care. He said building infrastructure and partnerships to support clinicians and maintain consistency is a priority, and that Medline's scale, expertise, and post-acute focus make it a strong partner as James River serves more patients. Why consistency matters as providers grow. Expanding home-based providers often add clinicians and locations quickly, which can produce variation in the supplies and documentation practices staff use. Standardizing on a single vendor and shared tools is one way to keep practices uniform across a growing network. Medline's perspective on the James River Home Health Medline Prime Vendor agreement. Renee Fisher, senior vice president of national field sales for post-acute care at Medline, said the company is proud to work with James River as it expands access to home-based care. She said the combination of reliable product access and post-acute supply chain solutions is meant to let James River's teams stay focused on patients and families. About Medline. Medline describes itself as the largest provider of medical-surgical products and supply chain solutions serving all points of care, employing more than 45,000 people worldwide and operating in more than 100 countries. The company trades on Nasdaq under MDLN and is headquartered in Northfield, Ill. How the James River Home Health Medline Prime Vendor agreement fits home-based care trends. The announcement reflects a theme raised at recent home-based care events, where operators said growth must rest on operational infrastructure and discipline. Supply chain reliability, clinical documentation, and compliance are part of that backbone, particularly as federal fraud enforcement and documentation scrutiny continue to affect home health and hospice providers. Why Wound documentation is a notable detail. Wound assessment and documentation are areas where consistent records matter for both clinical care and payer or regulatory review. Providing a standard tool for staff may help James River document care uniformly, though the announcement did not describe outcomes or metrics. What the James River Home Health Medline Prime Vendor agreement means going forward. The agreement gives James River a single supply and clinical program partner as it grows, and it gives Medline another post-acute customer. Because financial terms, contract length, and the size of James River's network were not disclosed, the practical impact on costs and operations cannot be assessed from the announcement alone. What to watch going forward. Observers will likely watch whether James River reports operational or clinical results from the Skin Health Program and NE1 Wound Tool, and whether more home health and hospice providers pursue similar prime vendor and clinical program bundles. As a company announcement, the James River Home Health Medline Prime Vendor news is best read as a signal of provider growth and vendor consolidation in post-acute care rather than as evidence of measured performance gains.

MDLN Stock Drop alert: Medline Stock plummets 13% after product quality issues revealed - BFA Law notifies investors of its ongoing Securities Fraud investigation. BFA Law is investigating whether Medline Inc. committed securities fraud relating to statements about Medline's manufacturing and product quality. NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit. Key Details of the Medline ($MDLN) Class Action Investigation: * Investigation Overview: Securities fraud relating to Medline's statements about its manufacturing and product quality. * Stock Declines: June 2, 2026 - 7% Stock Drop August 5, 2026 - 13% Stock Drop * Action: Contact BFA Law to discuss your rights Why is Medline Being Investigated for Securities Fraud? Medline is a healthcare manufacturing and supply-chain company that retails and distributes medical and surgical products. BFA is investigating whether Medline misled investors about its manufacturing and product quality. Why did Medline's Stock Drop? On June 2, 2026, the FDA published a warning letter detailing Medline's "significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals" and stating that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." Following that announcement, Medline shares fell approximately 7% on June 2, 2026. Then, before market hours on August 5, 2026, Medline acknowledged that at least some of remediation steps taken to address the issues in the FDA's warning letter had "result[ed] in earnings loss" during the company's 2Q26 earnings call. Following that announcement, Medline shares fell approximately 13% on August 5, 2026. What Can You Do? If you invested in Medline securities, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. Attorney advertising. Past results do not guarantee future outcomes.